论文部分内容阅读
目的:探讨B超选择性肝动脉化疗栓塞(TACE)联合经皮穿刺导管选择性门静脉化疗栓塞(SPVCE)治疗中晚期原发性肝癌(PHC)的价值。材料与方法:将133例中晚期PHC随机分成2组,对照单纯的选择性肝动脉化疗栓塞(TACE)与TACE加SPVCE的治疗效果。结果:TACE组和TACE加SPVCE总有效率[缓解和部分缓解(CR+PR)]分别为38%和59%,差异有显著意义(p<0.01),0.5、1、2年生存率TACE组分别为93.1%、65.4%、36.1%,TACE加SPVCE组分别为100%、95.1%、59.8%。两组差异有显著意义(p<0.01)。结论:TACE加SPVCE治疗中晚期PHC是一种有效的方法,效果优于单纯的TACE。
Objective: To evaluate the value of selective ultrasound-assisted transcatheter arterial chemoembolization (TACE) combined with selective portal vein chemoembolization (SPVCE) in the treatment of advanced primary liver cancer (PHC). Materials and Methods: 133 patients with advanced and advanced PHC were randomly divided into two groups to compare the therapeutic effects of selective hepatic arterial chemoembolization (TACE) and TACE plus SPVCE. Results: TACE group and TACE plus SPVCE total effective rate [remission and partial response (CR+PR)] were 38% and 59%, respectively, the difference was significant (p<0.01), 0.5, 1 and 2 year survival rates TACE group They were 93.1%, 65.4%, and 36.1%, respectively. TACE plus SPVCE group was 100%, 95.1%, and 59.8%, respectively. There was a significant difference between the two groups (p<0.01). Conclusion: TACE plus SPVCE is an effective method for the treatment of advanced PHC. The effect is better than TACE alone.